Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

24.35
-1.0800-4.25%
Pre-market: 24.600.2500+1.03%05:50 EDT
Volume:1.14M
Turnover:28.37M
Market Cap:1.67B
PE:-10.13
High:26.15
Open:25.58
Low:24.15
Close:25.43
52wk High:40.65
52wk Low:12.12
Shares:68.76M
Float Shares:44.33M
Volume Ratio:0.43
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:4.73
PE(LYR):-12.10

Loading ...

Tyra Bioscience announces $400M equity financing offering

TIPRANKS
·
Sep 15

Stock Market Today: S&P 500, Dow and Nasdaq Futures Face Pressure as Brent Nears $108 and FOMC Commences Two-Day Meet— MSTR, CRWD, BMM in Focus

Benzinga Earnings
·
Sep 15

Tyra Biosciences Shares up 4.4% Premarket After $400 Mln Equity Raise

THOMSON REUTERS
·
Sep 14

Tyra Biosciences Rises After $400 Mln Equity Raise

Reuters
·
Sep 14

Tyra Biosciences Prices USD 400 Million Stock, Pre-Funded Warrant Offering at USD 22.03 Per Share

Reuters
·
Sep 14

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Sep 14

Tyra Biosciences, - Announces Pricing of 9,079,000 Common Shares at $22.03 Per Share

THOMSON REUTERS
·
Sep 14

Tyra Biosciences Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Sep 14

Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead

TIPRANKS
·
Sep 12

Tyra Biosciences Director Rehan Verjee Buys $20,000 of Common Shares

Reuters
·
Sep 12

Tyra Biosciences Price Target Maintained with a $53.00/Share by Wedbush

Dow Jones
·
Sep 10

Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright

TIPRANKS
·
Sep 10

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Sep 09

Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

Tyra Biosciences Tumbles After Cancer Drug Misses Wall Street Expectations

Reuters
·
Sep 09

Tyra Biosciences Reports 79% Response Rate in Phase 2 Bladder Cancer Study of Dabogratinib at 60 Mg Dose

Reuters
·
Sep 09

Tyra Biosciences, - Announces Initial Phase 2 Surf302 Results for Oral Dabogratinib

THOMSON REUTERS
·
Sep 09

Tyra Biosciences to Present at Cantor Global Healthcare Conference 2026

Reuters
·
Sep 09